In the original article, there was a mistake in Table 3 as published. The administration form of satralizumab is “SC” not “IV.” The corrected Table 3 appears below.
Table 3
| Monoclonal antibody | Mechanism | Route | Risk | |
|---|---|---|---|---|
| Rituximab | Chimeric | CD20-B cell depletion | IV | Infections; Hepatitis B reactivation; Infusion-related reaction |
| Eculizumab | Humanized | C5 complement inhibitor | IV | Meningococcal infection; Possible PML risk; Infusion-related reaction |
| Satralizumab | Humanized recycling | IL-6 receptor blocker | SC | |
| Tocilizumab | Humanized | IL-6 receptor blocker | SC | Cardiovascular risk; Cholesterol levels |
| Inebelizumab | Humanized | CD19-B cell depletion | IV | Infections; Infusion-related reaction |
| Ofatumumab | Fully humanized | CD20-B cell depletion | SC | Infections; Infusion-related reaction; Hepatitis B reactivation |
| Ocrelizumab | Humanized | CD20-B cell depletion | IV | Infections; Infusion-related reaction; Hepatitis B reactivation |
Immunosuppressive molecules for attack prevention in NMOSD.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
pediatric, neuroinflammation, NMOSD, MOG, treatment, diagnosis
Citation
Tenembaum S, Yeh EA and The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC) (2021) Corrigendum: Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front. Pediatr. 8:642203. doi: 10.3389/fped.2020.642203
Received
15 December 2020
Accepted
16 December 2020
Published
15 February 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
8 - 2020
Updates
Copyright
© 2021 Tenembaum, Yeh and The Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC).
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: E. Ann Yeh ann.yeh@sickkids.ca
This article was submitted to Pediatric Neurology, a section of the journal Frontiers in Pediatrics
†See Appendix for complete list of active GJCF-ICC Members
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.